|
|
|
|
426
|
Tue, 7/30/2019,
3:05 PM -
3:50 PM
|
CC-Hall C
|
|
SPEED: Biopharmaceutical and General Health Studies: Statistical Methods and Applications, Part 2 — Contributed Poster Presentations
|
|
Biopharmaceutical Section, Health Policy Statistics Section, ENAR
|
|
Chair(s): Sedigheh Mirzaei Salehabadi, St. Jude Children's Research Hospital
|
|
Oral Presentations
for this session.
|
|
1:
|
Mediation Analysis for Longitudinal Data with Applications to Clinical Trial Data
Yun Zhang
|
|
2:
|
An Adaptive Phase II Dose Finding Study Using Sample Size Re-Estimation Design
Qingyang Liu, University of Connecticut; Guanyu Hu, University of Connecticut; Yaoshi Wu, Boehringer-Ingelheim ; Binqi Ye, Boehringer-Ingelheim; Susan Wang, Boehringer-Ingelheim
|
|
4:
|
Quantifying the Number of Events Borrowed from External Data in Hybrid Control Arms
Brian Segal, Flatiron Health; Carrie Bennette, Flatiron Health; Somnath Sarkar, Flatiron Health
|
|
5:
|
Characterizing Irreproducibility in Drug Sensitivity Data from a Large Pharmacogenomic Study
Zoe Rehnberg, University of Michigan; Johann A Gagnon-Bartsch, University of Michigan
|
|
6:
|
Closest Similar Subset Imputation
Macaulay Okwuokenye, Brio Dexteri Pharmaceutical Consultant & UNE; Karl E Peace, Georgia Southern University
|
|
7:
|
Planning and Analyzing Clinical Trials with Competing Risks: Recommendations for Choosing Appropriate Statistical Methodology
Misun Yu Lee, Astellas Pharma; Joseph Poythress, University of Georgia; James Young, Astellas Pharma
|
|
8:
|
Estimating and Using the Attained Power Distribution to Ensure We Get the Trial Power We Expect
Yongdong Ouyang, University of British Columbia; Hubert Wong, University of British Columbia; Ehsan Karim, University of British Columbia; Paul Gustafson, University of British Columbia
|
|
9:
|
Bayesian Semiparametric Joint Modeling of Longitudinal Predictors and a Binary Outcome
Woobeen Lim, The Ohio State University; Michael Pennell, Ohio State University
|
|
10:
|
Clustering of Multivariate Data with Varying Dimensions
Xiaoqi Lu, Columbia University; Bin Cheng, Columbia University; Ying Kuen Ken Cheung, Columbia University
|
|
11:
|
Sieve Maximum Likelihood Method for Interval-Censored Data with Missing Covariates Under Proportional Hazards Model
Ruiwen Zhou, University of Missouri-Columbia; Huiqiong Li, Yunnan University; (Tony) Jianguo Sun, University of Missouri
|
|
12:
|
Adjusting Response Adaptive Allocation for Subject Dropout
Katharine Stromberg, Virginia Commonwealth University; Adam Sima, Virginia Commonwealth University
|
|
13:
|
Estimating the Relative Risk for Response-Biased Samples: Calibration and Conditional Likelihood
Claudia Rivera-Rodriguez, University of Auckland
|
|
14:
|
The Use of a New Classifier to Maximize the Classification Performance
Hua Ma, Merck; Joe Heyse, Merck
|
|
15:
|
Reproducibility of Living Data - Validation of Published Research Using the Parkinson’s Progression Marker Initiative Living Database
Elliot Burghardt, University of Iowa; Christopher Coffey, University of Iowa; Chelsea Caspell-Garcia, University of Iowa; Eric Foster, Ferring Pharmaceuticals
|
|
16:
|
Blinding in Open Label Study with Adaptive Design
Bo Xu, Boston Biomedical Inc; Bo Jin, Boston Biomedical Inc; Alex Dmitrienko, Mediana Inc
|
|
17:
|
Another Estimation Method Besides MMRM for Treatment Effects in Diabetes Clinical Trials
Yu Du, Eli Lilly and Company
|
|
18:
|
Criteria for Choosing a Futility Method for Clinical Studies
Richard McNally, Covance-Chiltern
|
|
19:
|
Random Forests for Exploring Factors Driving Opioid Prescribing in National Outpatient Health Care Data Using Complex Survey Design
Yong Ma, FDA; JaeJoon Song, FDA
|
